Macrophage pro-inflammatory cytokine secretion is enhanced following interaction with autologous platelets
© Scull et al; licensee BioMed Central Ltd. 2010
Received: 16 June 2010
Accepted: 11 November 2010
Published: 11 November 2010
Macrophages are the dominant phagocyte at sites of wound healing and inflammation, and the cellular and acellular debris encountered by macrophages can have profound effects on their inflammatory profile. Following interaction with apoptotic cells, macrophages are known to switch to an anti-inflammatory phenotype. Activated platelets, however, are also a major component of inflammatory lesions and have been proposed to be pro-inflammatory mediators. In the present study, we tested the hypothesis that macrophage interaction with activated platelets results in an inflammatory response that differs from the response following phagocytosis of apoptotic cells.
Human monocyte-derived macrophages (hMDMs) were co-incubated with autologous activated platelets (AAPs) and the platelet-macrophage interaction was examined by electron microscopy and flow cytometry. The cytokines TNF-α, IL-6, and IL-23 were also measured during LPS-activated hMDM co-incubation with AAPs, which was compared to co-incubation with apoptotic lymphocytes. Cytokine secretion was also compared to platelets pre-treated with the gluococorticoid dexamethasone.
Macrophages trapped and phagocytized AAPs utilizing a mechanism that was significantly inhibited by the scavenger receptor ligand fucoidan. LPS-induced macrophage secretion of TNF-α, IL-6, and IL-23 was inhibited by co-incubation with apoptotic cells, but enhanced by co-incubation with AAPs. The platelet-dependent enhancement of LPS-induced cytokines could be reversed by pre-loading the platelets with the glucocorticoid dexamethasone.
The interaction of human macrophages with autologous platelets results in scavenger-receptor-mediated platelet uptake and enhancement of LPS-induced cytokines. Therefore, the presence of activated platelets at sites of inflammation may exacerbate pro-inflammatory macrophage activation. The possibility of reversing macrophage activation with dexamethasone-loaded platelets is a promising therapeutic approach to treating unresolved inflammation.
A major function of macrophages is phagocytosis of cellular and acellular debris during inflammation and wound healing, and the activation response of macrophages following phagocytosis can be varied depending on the local extracellular environment [1–6]. The importance of phagocytosis in the resolution of inflammation is emphasized by pathological conditions involving impaired phagocytosis, which may manifest as persistent infections or chronic inflammatory lesions such as diabetic ulcers and atherosclerotic plaques [7–11].
During their differentiation from primary monocytes, macrophages acquire specialized receptors and machinery for recognizing and clearing both apoptotic and infected cells . In clearing apoptotic cells, macrophages use receptors such as scavenger receptors and integrins that function independently or in cooperation with each other depending on the type of cell targeted for phagocytosis [13–19].
Platelets are anucleate cells which play an integral role in maintaining vascular integrity. Within their 8-10 day lifespan, platelets can become activated either in the circulation or during adherence at a site of injury, and during this process they become targeted for destruction by macrophages . The process of platelet activation involves several changes to the cell surface, including expression of P-selectin and loss of membrane asymmetry [21–23]. These changes in the platelet membrane may provide molecular signals to macrophages that trigger phagocytosis, although the precise mechanism by which macrophages recognize and phagocytose activated platelets remains to be identified.
Cells that have become apoptotic as part of their normal life cycle are recognized and cleared by phagocytosis in a manner that usually inhibits pro-inflammatory responses [24–27]. Although circulating platelets can exert a pro-inflammatory effect on circulating monocytes [28, 29], their effect on differentiated macrophages, particularly at sites of inflammation, is not clear. We show here that phagocytosis of autologous platelets results in an pro-inflammatory profile that is opposite to the macrophage response following phagocytosis of apoptotic cells. Importantly, the platelet-enhanced, pro-inflammatory response of macrophages can be inhibited when the platelets are loaded with the glucocorticoid dexamethasone. In addition to novel insight into the macrophage inflammatory profile that exists in several diseases, these results also provide evidence that platelet-macrophage interactions are an important therapeutic target for reducing inflammation.
Human monocytes were isolated and cultured using techniques similar to those previously described [30, 31]. Briefly, blood from healthy human donors was collected into citrate and peripheral blood mononuclear cells (PBMCs) were isolated by using Lymphoprep (Accurate Chemical) according to the manufacturer's instructions. Monocytes were further isolated by plating the PBMCs on gelatin-coated tissue culture flasks for 45 min at 37°C followed by 10 washes with phosphate buffered saline (PBS) to remove non-adherent lymphocytes. Monocytes were then detached from the flasks by incubation in 10 mM EDTA for 2 min at 37°C. Monocytes (250,000 in 500 μl volume) were then plated in 24-well plates overnight in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) and 10 ng/ml recombinant human GM-CSF (R&D Systems). Monocytes were plated on glass coverslips for scanning electron microscopy (SEM) analysis and plastic tissue-culture plates for TEM analysis and phagocytosis experiments. Media was changed on day 2 and day 5, and after 7 days of culture the MDMs were used for phagocytosis and cytokine assays.
Platelets were isolated from whole blood collected into acid-citrate-dextrose (ACD) from healthy human donors and centrifuged for 15 min at 500 × g to generate platelet-rich plasma (PRP). PRP was pelleted by centrifugation for 10 min at 800 × g and the platelet pellet subsequently washed 2 times in citrated saline (pH 6.8). A portion of the platelet samples were degranulated by incubating 1 ml of platelets (250,000/μl in citrated saline) with 10 μl of 10 μM calcium ionophore A21387 (Sigma) for 15 min with rocking at room temperature, followed by three centrifugational washes with citrated saline. For phagocytosis experiments, platelets were fluorescently labeled with Cell Tracker Green CMFDA (Invitrogen) as previously described . After the final wash, and prior to use in phagocytosis assays, platelets were resuspended in warm serum-free RPMI for 15 min at 37°C.
For analysis of surface P-selectin and phosphatidylserine, platelets (250,000/μl) were first incubated in either citrated saline or serum-free RMPI media for 1 hr at 37°C. A portion of the platelets were activated by including thrombin (King Pharmaceuticals, 1 U/ml final concentration) in the incubation reaction. To detect surface expression of activation markers in each platelet treatment group, a 10 μl aliquot of platelets was stained with either FITC-anti-CD62P (Biolegend) or FITC-Annexin-V (Biolegend) for 30 min at room temperature, after which the cells were fixed and analyzed immediately by flow cytometry. Flow cytometry analysis was performed using a CyAn flow cytometer (Beckman Coulter) and the Summit analysis software.
Dexamethasone-loaded platelets were prepared by incubating 1 ml of platelets (250,000/ul) in citrated saline with 5 ul of dexamethasone (Sigma, 10 mM in DMSO) for 15 min on a rocker at room temperature. Platelets were then washed three times with citrated saline to remove unbound dexamethasone. For subsequent experiments, 5 × 106 dex-platelets were added to each well of macrophages in a 24-well plate.
To prepare apoptotic cells, PBMCs were isolated as above, and following monocyte-adherence to gelatin-coated flasks the non-adherent lymphocytes were collected. Cells were rendered apoptotic (Annexin-V positive) by UV-irradiation for 10 min followed by overnight incubation in RPMI + 10% FBS at 37°C + 5% CO2.
Thirty minutes prior to the start of each experiment, 7-day old MDMs were washed 3 times with PBS and incubated with 500 μl fresh RPMI media. In some experiments the media was supplemented with 10% autologous human serum. A 25 μl aliquot of fluorescently labeled platelets (250,000/μl) was added to each well of macrophages. Platelets and macrophages were co-incubated for 45 min.
For SEM analysis, the co-cultures were washed once with PBS and fixed in 2% paraformaldehyde and 0.5% glutaraldehyde. The samples were then processed as previously described  and examined using a Cambridge S200 scanning electron microscope at 20 kV. For TEM analysis, the co-cultures were washed 5 times with PBS and fixed in 2% paraformaldehyde, processed as previously described , and examined using a Leo EM 910 transmission electron microscope. For flow cytometric analysis, warm trypsin/EDTA was then added to the macrophages to remove adherent platelets (confirmed by microscopy) and cells were incubated 15 min at 37°C. Macrophages were then collected and fixed in 1% cold paraformaldehyde and analyzed using a CyAn flow cytometer (Beckman Coulter) and the Summit analysis software. Data is expressed as the percentage of FL1-positive macrophages in a given collection of 10,000 macrophages. Data shown represent the average of at least 3 independent experiments and for each experiment 10,000 macrophages were analyzed.
Latrunculin (Sigma, 1 μg/ml final concentration), used as a pan-phagocytosis inhibitor, was added to a portion of macrophage-containing wells 30 min prior to addition of platelets. Fucoidan (Sigma) was added to macrophages at a final concentration of 250 μg/ml 30 min prior to addition of platelets.
Each well of MDMs was washed 3 times with PBS and incubated with fresh RPMI + 10% autologous human serum. Activated, degranulated, or dexamethasone-loaded platelets (5 × 106) were added to each well in addition to LPS (100 ng/ml). Some samples also received dexamethasone alone at a final concentration of 1 μM. After 24 hrs, supernatants were collected, spun 10 min at 14,000 g, and frozen at -80°C. Cytokines were measured by ELISA using capture and detection antibodies (eBioscience) per the manufacturer's instructions. Cytokines were measured in duplicate and averaged. The amount of protein secreted was normalized to the amount secreted by macrophages treated with LPS alone. Each experiment was performed at least 3 times using 3 different MDM donors. In each experiment, the platelets added were from the same donor as the MDMs. Treatment groups were compared using an unpaired t-test.
Macrophage Phagocytosis of Autologous Platelets
Platelet Activation in Co-Culture Conditions
citrated saline control
15.2 +/- 3.0
8.9 +/- 0.9
RPMI 1 hour
178.5 +/- 33.1
11.3 +/- 3.1
1471.3 +/- 155.8
1599.9 +/- 464.5
Inflammatory Cytokines are Enhanced Following Platelet Phagocytosis
The hypothesis that macrophage phagocytosis of activated platelets results in an inflammatory response that differs from the response following phagocytosis of apoptotic cells was tested by measuring the secretion of cytokines following addition of platelets or apoptotic cells to LPS-stimulated hMDMs. Autologous platelets in two different activation states were used in the co-culture experiments: platelets that were "partially activated" (with surface exposure of measurable quantities of P-selectin and CD40L) by preparing in serum-free media or "irreversibly activated" (with phosphatidylserine exposure in addition to P-selectin) by treatment with the calcium ionophore A23187 .
The inflammatory response of the hMDMs was assessed by measuring the levels of TNF-α, IL-6, and IL-23 after incubation with autologous primed platelets, autologous activated platelets, or control apoptotic leukocytes in the presence of LPS for 24 hours. As an additional control, we analyzed "platelets-only" cultures using the same media and incubation times as the platelet-macrophage co-cultures and were unable to detect any TNF-α, IL-6, or IL-23 in platelets alone (with or without LPS, data not shown). We therefore conclude that the cytokines secreted in this system are macrophage-derived, and in each experiment the cytokine levels were normalized to the amount of cytokine secreted by hMDMs incubated with LPS alone.
Based on the knowledge that platelets can bind glucocorticoids via glucocorticoid receptors , we tested the hypothesis that glucocorticoid-bound platelets would be less inflammatory than platelets that are activated, but otherwise unmodified. Platelets were incubated with dexamethasone, then unbound glucocorticoid was removed by washing the platelets in citrated saline. Although it is unlikely that all of the dexamethasone becomes bound to the platelets, complete retention of the dexamethasone would yield a final concentration in the DEX-plt stock of 50 μM and a final (effective) concentration in the platelet-macrophage co-cultures of 1 μM. As shown in Figure 3B (striped bars), the levels of cytokines produced after co-culture with dexamethasone-loaded platelets were inhibited to 30-50% of the levels produced by stimulation with LPS alone. The dexamethasone-loaded platelets had a similar effect on cytokine secretion as 1 μM dexamethasone alone. These results indicate that the pro-inflammatory platelet effect on macrophage activation can be reversed by pre-loading the platelets with glucocorticoids.
Phagocytosis is an important means of clearing both immunologically compromised and apoptotic cells. Monocyte-derived macrophages are efficient phagocytes in organs of the reticuloendothelial system and within injured tissues; however, the process of platelet clearance by macrophages is poorly understood. This work has demonstrated phagocytosis of fresh autologous activated platelets (AAPs) by monocyte-derived macrophages using an entirely human-derived in vitro system. In this system, uptake of freshly isolated platelets is dependent on actin polymerization, but occurs independently of any soluble serum factors. Additionally, phagocytosis of platelets is enhanced with platelet activation.
Previous studies on platelet phagocytosis have focused on modified platelets such as chilled platelets, opsonized platelets, and aged platelets [39–46], each of which involves distinct changes to the platelet surface. Aged platelets most closely resemble freshly activated platelets because during aging platelets increase expression of phosphatidylserine and P-selectin . Interestingly, Brown et al. have also shown in vitro that phagocytosis of aged platelets is mediated by scavenger receptors . Therefore, macrophages may recognize freshly activated platelets in the same way that they clear aged platelets. The finding that phosphatidylserine exposure is not a requirement for phagocytosis of AAPs in the present study was somewhat unexpected, considering that phosphatidylserine is a well documented 'eat me' signal for the phagocytosis of many different types of cells undergoing apoptosis [47–50].
Because phagocytosis correlates with platelet activation, we would expect no phagocytosis to occur in the presence of quiescent platelets. However, RPMI media alone causes platelet activation (Table 1), probably due to the presence of low levels of calcium and phosphate. Additionally, the use of platelet inhibitors such as aspirin, EDTA, or prostaglandin, which may have maintained the platelets in a resting state, could not be used because they directly affect macrophage function [51, 52]. Thus, one disadvantage of our system is that the platelet-macrophage interaction using activated platelets could not be compared to an interaction in which the platelets were in a truly resting state. Nonetheless, the interaction involving activated platelets is relevant because platelets are most likely activated at sites of tissue injury and perhaps during removal in the spleen. Thus, the interaction involving activated platelets was the focus of this work.
The macrophage response following phagocytosis of cells expressing surface phosphatidylserine is usually immunosuppressive [2, 26, 27, 53, 54]. In the present study, co-culture with apoptotic cells inhibited production of pro-inflammatory cytokines by LPS-activated macrophages. These results are in agreement with previous findings for TNF-α, IL-1β, IL-8, IL-12 [2, 4, 55, 56], and are extended to now include IL-6 and IL-23.
In contrast to the effect of apoptotic cells, activated platelets enhanced pro-inflammatory cytokine secretion from LPS-activated macrophages. The cytokines measured in the current study, TNF-α, IL-6 and IL-23, are significant readouts because they are known to be secreted by macrophages, but not platelets, and they play important roles in mediating pro-inflammatory responses. Interestingly, the pro-inflammatory cytokine secretion was also enhanced by platelets with surface phosphatidylserine exposure. The finding that degranulated platelets, washed free from their secreted proteins, also enhanced LPS-induced macrophage cytokine secretion suggests that a secreted platelet factor is not likely to be responsible for this effect. However, a secreted platelet factor could exert the observed effect if it remained bound to the platelet surface after secretion from the platelet. Because the platelets remained in the co-incubation for the entire experiment (24 hrs), the possibility also exists that the inflammatory consequences of platelet-macrophage interactions occur independently of phagocytosis. Cell contact itself could be responsible for the observed effects. Nonetheless, we have shown the pro-inflammatory effect of platelets does occur in conditions which favor platelet uptake (Figure 1).
Recent studies have highlighted additional roles of platelets beyond hemostasis, particularly with respect to platelet-mediated effects on inflammation [28, 57, 58]. These results are particularly relevant to chronic inflammatory diseases, during which macrophages may interact with apoptotic or necrotic cells, as well as platelets, for prolonged periods of time. Studies in mice have demonstrated that depletion of platelets or platelet proteins affects macrophage infiltration and inflammation in lesions of the skin, joints, gut, and vasculature [59–63]. Although the precise mechanisms by which platelets impact macrophage activation remain unclear, the current study provides direct evidence, using human cells, of specific macrophage cytokines that are enhanced by activated platelets.
Pro-inflammatory cytokines secreted by macrophages can also exert effects on surrounding cells and tissues. For example, IL-6 and IL-23 stimulate T-cells for induction of Th17 immune responses, which are operant in autoimmune diseases such as inflammatory bowel disease, lupus, psoriasis and arthritis [64–67]. We speculate, therefore, that in addition to amplifying general pro-inflammatory responses, platelet-macrophage interactions might also play a role in Th17-mediated autoimmune diseases.
Glucocorticoids such as dexamethasone can exert powerful immunosuppressive effects on leukocytes and are thus an attractive therapy for modulating inflammation . After steroid binding to glucocorticoid receptors, which occurs within the cytoplasm, activated glucocorticoid receptors translocate to the nucleus and inhibit transcription of a variety of pro-inflammatory cytokines . We speculate, therefore, that the immunosuppressive action of dexamethasone-loaded platelets occurs by facilitating delivery of dexamethasone to macrophage glucocorticoid receptors. Because macrophage glucocorticoid receptors are cytoplasmic, we further speculate that the immunosuppressive effect of dex-platelets is a result of phagocytosis. The use of dexamethasone-loaded platelets for modulating macrophage action may prove useful in treating diseases characterized by excessive and unresolving inflammation. Our results demonstrating similar levels of immunosuppression with both free dexamethasone and dexamethasone bound to platelets suggests that tethering glucocorticoids to platelets may increase drug targeting and reduce the need for high systemic doses of glucocorticoids, which can have unwanted side effects . Furthermore, given the role of IL-6 and IL-23 in Th17-mediated inflammatory responses, the platelet-macrophage interaction is therefore a rational pharmacological target for inhibiting some Th17-related diseases.
We have shown here that the interaction of human macrophages with autologous platelets results in scavenger-receptor-mediated platelet uptake and enhancement of LPS-induced cytokine secretion. Given the presence of activated platelets together with macrophages during the response to injury and during inflammation, activated platelets at sites of inflammation most likely exacerbate the macrophage response. The presence of platelets must therefore be carefully considered when studying the cellular interactions occurring in inflammatory lesions.
We have also presented evidence here that platelets can be engineered to exert anti-inflammatory effects on macrophages. Given the emerging role of platelets in inflammatory diseases, the possibility of reversing macrophage activation with dexamethasone-loaded platelets is a promising therapeutic approach to treating unresolved inflammation.
This work was supported by sponsored research funds from Entegrion, Inc. (Research Triangle Park, NC, USA) and a collaborative research grant from the North Carolina Biotechnology Center.
- Aderem A: Phagocytosis and the inflammatory response. J Infect Dis. 2003, 187 (Suppl 2): S340-345. 10.1086/374747.PubMedView ArticleGoogle Scholar
- Chung EY, Kim SJ, Ma XJ: Regulation of cytokine production during phagocytosis of apoptotic cells. Cell Res. 2006, 16: 154-161. 10.1038/sj.cr.7310021.PubMedView ArticleGoogle Scholar
- Birge RB, Ucker DS: Innate apoptotic immunity: the calming touch of death. Cell Death Differ. 2008, 15: 1096-1102. 10.1038/cdd.2008.58.PubMedView ArticleGoogle Scholar
- Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM: Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest. 1998, 101: 890-898. 10.1172/JCI1112.PubMedPubMed CentralView ArticleGoogle Scholar
- Li Y, Gerbod-Giannone MC, Seitz H, Cui D, Thorp E, Tall AR, Matsushima GK, Tabas I: Cholesterol-induced apoptotic macrophages elicit an inflammatory response in phagocytes, which is partially attenuated by the Mer receptor. J Biol Chem. 2006, 281: 6707-6717. 10.1074/jbc.M510579200.PubMedView ArticleGoogle Scholar
- Henson PM, Hume DA: Apoptotic cell removal in development and tissue homeostasis. Trends Immunol. 2006, 27: 244-250. 10.1016/j.it.2006.03.005.PubMedView ArticleGoogle Scholar
- Rosqvist R, Bolin I, Wolf-Watz H: Inhibition of phagocytosis in Yersinia pseudotuberculosis: a virulence plasmid-encoded ability involving the Yop2b protein. Infect Immun. 1988, 56: 2139-2143.PubMedPubMed CentralGoogle Scholar
- Casanova JL, Abel L: Revisiting Crohn's disease as a primary immunodeficiency of macrophages. J Exp Med. 2009, 206: 1839-1843. 10.1084/jem.20091683.PubMedPubMed CentralView ArticleGoogle Scholar
- Oncul O, Yildiz S, Gurer US, Yeniiz E, Qyrdedi T, Top C, Gocer P, Akarsu B, Cevikbas A, Cavuslu S: Effect of the function of polymorphonuclear leukocytes and interleukin-1 beta on wound healing in patients with diabetic foot infections. J Infect. 2007, 54: 250-256. 10.1016/j.jinf.2006.05.004.PubMedView ArticleGoogle Scholar
- Maree AF, Komba M, Finegood DT, Edelstein-Keshet L: A quantitative comparison of rates of phagocytosis and digestion of apoptotic cells by macrophages from normal (BALB/c) and diabetes-prone (NOD) mice. J Appl Physiol. 2008, 104: 157-169. 10.1152/japplphysiol.00514.2007.PubMedView ArticleGoogle Scholar
- Tabas I: Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol. 2005, 25: 2255-2264. 10.1161/01.ATV.0000184783.04864.9f.PubMedView ArticleGoogle Scholar
- Mukhopadhyay S, Pluddemann A, Gordon S: Macrophage pattern recognition receptors in immunity, homeostasis and self tolerance. Adv Exp Med Biol. 2009, 653: 1-14. full_text.PubMedView ArticleGoogle Scholar
- Albert ML, Kim JI, Birge RB: alphavbeta5 integrin recruits the CrkII-Dock180-rac1 complex for phagocytosis of apoptotic cells. Nat Cell Biol. 2000, 2: 899-905. 10.1038/35046549.PubMedView ArticleGoogle Scholar
- Fadok VA, Savill JS, Haslett C, Bratton DL, Doherty DE, Campbell PA, Henson PM: Different populations of macrophages use either the vitronectin receptor or the phosphatidylserine receptor to recognize and remove apoptotic cells. J Immunol. 1992, 149: 4029-4035.PubMedGoogle Scholar
- Fadok VA, Warner ML, Bratton DL, Henson PM: CD36 is required for phagocytosis of apoptotic cells by human macrophages that use either a phosphatidylserine receptor or the vitronectin receptor (alpha v beta 3). J Immunol. 1998, 161: 6250-6257.PubMedGoogle Scholar
- Gregory CD: CD14-dependent clearance of apoptotic cells: relevance to the immune system. Curr Opin Immunol. 2000, 12: 27-34. 10.1016/S0952-7915(99)00047-3.PubMedView ArticleGoogle Scholar
- Hart SP, Dransfield I, Rossi AG: Phagocytosis of apoptotic cells. Methods. 2008, 44: 280-285. 10.1016/j.ymeth.2007.11.009.PubMedView ArticleGoogle Scholar
- Platt N, Suzuki H, Kurihara Y, Kodama T, Gordon S: Role for the class A macrophage scavenger receptor in the phagocytosis of apoptotic thymocytes in vitro. Proc Natl Acad Sci USA. 1996, 93: 12456-12460. 10.1073/pnas.93.22.12456.PubMedPubMed CentralView ArticleGoogle Scholar
- Savill J, Fadok V, Henson P, Haslett C: Phagocyte recognition of cells undergoing apoptosis. Immunol Today. 1993, 14: 131-136. 10.1016/0167-5699(93)90215-7.PubMedView ArticleGoogle Scholar
- Brown SB, Clarke MC, Magowan L, Sanderson H, Savill J: Constitutive death of platelets leading to scavenger receptor-mediated phagocytosis. A caspase-independent cell clearance program. J Biol Chem. 2000, 275: 5987-5996. 10.1074/jbc.275.8.5987.PubMedView ArticleGoogle Scholar
- Andre P: P-selectin in haemostasis. Br J Haematol. 2004, 126: 298-306. 10.1111/j.1365-2141.2004.05032.x.PubMedView ArticleGoogle Scholar
- Zwaal RF, Bevers EM: Platelet phospholipid asymmetry and its significance in hemostasis. Subcell Biochem. 1983, 9: 299-334.PubMedView ArticleGoogle Scholar
- Heemskerk JW, Bevers EM, Lindhout T: Platelet activation and blood coagulation. Thromb Haemost. 2002, 88: 186-193.PubMedGoogle Scholar
- Djaldetti M, Salman H, Bergman M, Djaldetti R, Bessler H: Phagocytosis--the mighty weapon of the silent warriors. Microsc Res Tech. 2002, 57: 421-431. 10.1002/jemt.10096.PubMedView ArticleGoogle Scholar
- Ravichandran KS, Lorenz U: Engulfment of apoptotic cells: signals for a good meal. Nat Rev Immunol. 2007, 7: 964-974. 10.1038/nri2214.PubMedView ArticleGoogle Scholar
- Gregory CD, Devitt A: The macrophage and the apoptotic cell: an innate immune interaction viewed simplistically?. Immunology. 2004, 113: 1-14. 10.1111/j.1365-2567.2004.01959.x.PubMedPubMed CentralView ArticleGoogle Scholar
- Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I: Immunosuppressive effects of apoptotic cells. Nature. 1997, 390: 350-351. 10.1038/37022.PubMedView ArticleGoogle Scholar
- Smyth SS, McEver RP, Weyrich AS, Morrell CN, Hoffman MR, Arepally GM, French PA, Dauerman HL, Becker RC: Platelet functions beyond haemostasis. J Thromb Haemost. 2009, 7 (11): 1759-66. 10.1111/j.1538-7836.2009.03586.x.PubMedView ArticleGoogle Scholar
- Weyrich AS, Lindemann S, Zimmerman GA: The evolving role of platelets in inflammation. J Thromb Haemost. 2003, 1: 1897-1905. 10.1046/j.1538-7836.2003.00304.x.PubMedView ArticleGoogle Scholar
- Jones BM, Nicholson JK, Holman RC, Hubbard M: Comparison of monocyte separation methods using flow cytometric analysis. J Immunol Methods. 1989, 125: 41-47. 10.1016/0022-1759(89)90076-8.PubMedView ArticleGoogle Scholar
- Hassan NF, Campbell DE, Douglas SD: Purification of human monocytes on gelatin-coated surfaces. J Immunol Methods. 1986, 95: 273-276. 10.1016/0022-1759(86)90415-1.PubMedView ArticleGoogle Scholar
- Baker GR, Sullam PM, Levin J: A simple, fluorescent method to internally label platelets suitable for physiological measurements. Am J Hematol. 1997, 56: 17-25. 10.1002/(SICI)1096-8652(199709)56:1<17::AID-AJH4>3.0.CO;2-5.PubMedView ArticleGoogle Scholar
- Fischer TH, Robbins ME, Bode AP, Nichols TC, Bellinger DE, Schoenfisch MH: Evidence that rehydrated, lyophilized red blood cells are sufficiently deformable for normal microcirculation transit. Microsc Res Tech. 2004, 65: 62-71. 10.1002/jemt.20106.PubMedView ArticleGoogle Scholar
- Sanders WE, Read MS, Reddick RL, Garris JB, Brinkhous KM: Thrombotic thrombocytopenia with von Willebrand factor deficiency induced by botrocetin. An animal model. Lab Invest. 1988, 59: 443-452.PubMedGoogle Scholar
- Nakamura T, Suzuki H, Wada Y, Kodama T, Doi T: Fucoidan induces nitric oxide production via p38 mitogen-activated protein kinase and NF-kappaB-dependent signaling pathways through macrophage scavenger receptors. Biochem Biophys Res Commun. 2006, 343: 286-294. 10.1016/j.bbrc.2006.02.146.PubMedView ArticleGoogle Scholar
- Krieger M, Herz J: Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu Rev Biochem. 1994, 63: 601-637.PubMedView ArticleGoogle Scholar
- White JG, Rao GH, Gerrard JM: Effects of the lonophore A23187 on blood platelets I. Influence on aggregation and secretion. Am J Pathol. 1974, 77: 135-149.PubMedPubMed CentralGoogle Scholar
- Moraes LA, Paul-Clark MJ, Rickman A, Flower RJ, Goulding NJ, Perretti M: Ligand-specific glucocorticoid receptor activation in human platelets. Blood. 2005, 106: 4167-4175. 10.1182/blood-2005-04-1723.PubMedView ArticleGoogle Scholar
- Hoffmeister KM, Felbinger TW, Falet H, Denis CV, Bergmeier W, Mayadas TN, von Andrian UH, Wagner DD, Stossel TP, Hartwig JH: The clearance mechanism of chilled blood platelets. Cell. 2003, 112: 87-97. 10.1016/S0092-8674(02)01253-9.PubMedView ArticleGoogle Scholar
- Badlou BA, Spierenburg G, Ulrichts H, Deckmyn H, Smid WM, Akkerman JW: Role of glycoprotein Ibalpha in phagocytosis of platelets by macrophages. Transfusion. 2006, 46: 2090-2099. 10.1111/j.1537-2995.2006.01034.x.PubMedView ArticleGoogle Scholar
- Badlou BA, Wu YP, Smid WM, Akkerman JW: Platelet binding and phagocytosis by macrophages. Transfusion. 2006, 46: 1432-1443. 10.1111/j.1537-2995.2006.00913.x.PubMedView ArticleGoogle Scholar
- Josefsson EC, Gebhard HH, Stossel TP, Hartwig JH, Hoffmeister KM: The macrophage alphaMbeta2 integrin alphaM lectin domain mediates the phagocytosis of chilled platelets. J Biol Chem. 2005, 280: 18025-18032. 10.1074/jbc.M501178200.PubMedView ArticleGoogle Scholar
- Babic AM, Josefsson EC, Bergmeier W, Wagner DD, Kaufman RM, Silberstein LE, Stossel TP, Hartwig JH, Hoffmeister KM: In vitro function and phagocytosis of galactosylated platelet concentrates after long-term refrigeration. Transfusion. 2007, 47: 442-451. 10.1111/j.1537-2995.2007.01134.x.PubMedView ArticleGoogle Scholar
- Bondanza A, Sabbadini MG, Pellegatta F, Zimmermann VS, Tincani A, Balestrieri G, Manfredi AA, Rovere P: Anti-beta2 glycoprotein I antibodies prevent the De-activation of platelets and sustain their phagocytic clearance. J Autoimmun. 2000, 15: 469-477. 10.1006/jaut.2000.0449.PubMedView ArticleGoogle Scholar
- Roubey RA: Immunology of the antiphospholipid syndrome: antibodies, antigens, and autoimmune response. Thromb Haemost. 1999, 82: 656-661.PubMedGoogle Scholar
- Roubey RA: Systemic lupus erythematosus, hypercoagulable states, and antiphospholipid antibodies. Arthritis Care Res. 1999, 12: 155-156. 10.1002/1529-0131(199906)12:3<155::AID-ART1>3.0.CO;2-#.PubMedView ArticleGoogle Scholar
- Wu Y, Tibrewal N, Birge RB: Phosphatidylserine recognition by phagocytes: a view to a kill. Trends Cell Biol. 2006, 16: 189-197. 10.1016/j.tcb.2006.02.003.PubMedView ArticleGoogle Scholar
- Bratosin D, Mazurier J, Tissier JP, Estaquier J, Huart JJ, Ameisen JC, Aminoff D, Montreuil J: Cellular and molecular mechanisms of senescent erythrocyte phagocytosis by macrophages. A review. Biochimie. 1998, 80: 173-195. 10.1016/S0300-9084(98)80024-2.PubMedView ArticleGoogle Scholar
- Schlegel RA, Callahan M, Krahling S, Pradhan D, Williamson P: Mechanisms for recognition and phagocytosis of apoptotic lymphocytes by macrophages. Adv Exp Med Biol. 1996, 406: 21-28.PubMedView ArticleGoogle Scholar
- Guzik K, Potempa J: Friendly fire against neutrophils: proteolytic enzymes confuse the recognition of apoptotic cells by macrophages. Biochimie. 2008, 90: 405-415. 10.1016/j.biochi.2007.09.008.PubMedView ArticleGoogle Scholar
- Lu L, Liu H, Peng J, Gan L, Shen L, Zhang Q, Li L, Zhang L, Su C, Jiang Y: Regulations of the key mediators in inflammation and atherosclerosis by aspirin in human macrophages. Lipids Health Dis. 2010, 9: 16-10.1186/1476-511X-9-16.PubMedPubMed CentralView ArticleGoogle Scholar
- Kunkel SL, Spengler M, May MA, Spengler R, Larrick J, Remick D: Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression. J Biol Chem. 1988, 263: 5380-5384.PubMedGoogle Scholar
- Aderem A, Underhill DM: Mechanisms of phagocytosis in macrophages. Annu Rev Immunol. 1999, 17: 593-623. 10.1146/annurev.immunol.17.1.593.PubMedView ArticleGoogle Scholar
- Maderna P, Godson C: Phagocytosis of apoptotic cells and the resolution of inflammation. Biochim Biophys Acta. 2003, 1639: 141-151.PubMedView ArticleGoogle Scholar
- Kim S, Elkon KB, Ma X: Transcriptional suppression of interleukin-12 gene expression following phagocytosis of apoptotic cells. Immunity. 2004, 21: 643-653. 10.1016/j.immuni.2004.09.009.PubMedView ArticleGoogle Scholar
- Lucas M, Stuart LM, Savill J, Lacy-Hulbert A: Apoptotic cells and innate immune stimuli combine to regulate macrophage cytokine secretion. J Immunol. 2003, 171: 2610-2615.PubMedView ArticleGoogle Scholar
- Leslie M: Cell biology. Beyond clotting: the powers of platelets. Science. 2010, 328: 562-564. 10.1126/science.328.5978.562.PubMedView ArticleGoogle Scholar
- Page CP: Platelets as inflammatory cells. Immunopharmacology. 1989, 17: 51-59. 10.1016/0162-3109(89)90008-8.PubMedView ArticleGoogle Scholar
- Katoh N: Platelets as versatile regulators of cutaneous inflammation. J Dermatol Sci. 2009, 53: 89-95. 10.1016/j.jdermsci.2008.08.019.PubMedView ArticleGoogle Scholar
- Boilard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, Weinblatt ME, Massarotti EM, Remold-O'Donnell E, Farndale RW, Ware J, Lee DM: Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science. 2010, 327: 580-583. 10.1126/science.1181928.PubMedPubMed CentralView ArticleGoogle Scholar
- Danese S, de la Motte C, Sturm A, Vogel JD, West GA, Strong SA, Katz JA, Fiocchi C: Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology. 2003, 124: 1249-1264. 10.1016/S0016-5085(03)00289-0.PubMedView ArticleGoogle Scholar
- Wagner DD, Burger PC: Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol. 2003, 23: 2131-2137. 10.1161/01.ATV.0000095974.95122.EC.PubMedView ArticleGoogle Scholar
- Kockx MM, Cromheeke KM, Knaapen MW, Bosmans JM, De Meyer GR, Herman AG, Bult H: Phagocytosis and macrophage activation associated with hemorrhagic microvessels in human atherosclerosis. Arterioscler Thromb Vasc Biol. 2003, 23: 440-446. 10.1161/01.ATV.0000057807.28754.7F.PubMedView ArticleGoogle Scholar
- Brand S: Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut. 2009, 58: 1152-1167. 10.1136/gut.2008.163667.PubMedView ArticleGoogle Scholar
- Mangini AJ, Lafyatis R, Van Seventer JM: Type I interferons inhibition of inflammatory T helper cell responses in systemic lupus erythematosus. Ann N Y Acad Sci. 2007, 1108: 11-23. 10.1196/annals.1422.002.PubMedView ArticleGoogle Scholar
- Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S: Type 17 T helper cells-origins, features and possible roles in rheumatic disease. Nat Rev Rheumatol. 2009, 5: 325-331. 10.1038/nrrheum.2009.80.PubMedView ArticleGoogle Scholar
- van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, Cornelissen F, Mus AM, Florencia E, Prens EP, Lubberts E: Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009, 182: 5836-5845. 10.4049/jimmunol.0802999.PubMedView ArticleGoogle Scholar
- Barnes PJ: Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond). 1998, 94: 557-572.View ArticleGoogle Scholar
- McDonough AK, Curtis JR, Saag KG: The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol. 2008, 20: 131-137. 10.1097/BOR.0b013e3282f51031.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.